Datafin

Data-driven stock analysis platform for global investors.

Sitemap
HomeScreenerValuationSector Analysis
Resources
LibraryDatafin GuideMetric MethodologyValuation MethodologiesFAQPricingWho Is Datafin?Communication
Legal
Privacy PolicyTerms of UseCookie PolicyKVKK NoticeRefund Policy
Data Sources

Financial data sourced from official regulatory filings and verified market data providers. Metrics calculated using GAAP/IFRS standards.

Disclaimer

The analyses and visuals on this site are for informational purposes only and do not constitute investment advice.

Investment decisions involve risk. Verify data independently and consult a licensed advisor when needed.

© 2026 Datafin Financial Data Analysis Systems. All rights reserved.

Last updated: April 2026

CRNX PEER ANALYSIS

Crinetics Pharmaceuticals Inc — metric-by-metric comparison with peers and the industry median

CRNXCrinetics Pharmaceuticals Inc

🇺🇸 USA · NASDAQ · Healthcare · Biotechnology

Value itDuel
PriceFinancialsPeers

Overall Profile & Returns

· Biotechnology

Position Within Industry

0 = weak quartile, 100 = strong quartile
ValuationProfitabilityGrowthFinancial Health
CRNXIndustry median

Scores normalize each metric against industry quartiles (p25–p75); direction is inverted for lower-is-better metrics.

Return Comparison

1-Year
Split-adjusted
CRNX+41.0%TLX-28.2%MSB+27.6%CSL-47.6%
Year-to-Date (YTD)
CRNX-9.7%TLX+55.2%MSB-23.5%CSL-27.1%
1-Year
Split-adjusted
CRNX+41.0%VKTX+37.3%ACAD+23.0%EWTX+207.8%TNGX+425.3%DNLI+75.2%
Year-to-Date (YTD)
CRNX-9.7%VKTX+10.0%ACAD-3.5%EWTX+61.6%TNGX+237.9%DNLI+55.9%

Key Metric Comparison

P/E

Lower is better
CRNX—TLX—MSB—CSL30.02Median 17.81

ROE

Higher is better
CRNX-39.2%TLX-1.8%MSB-11.3%CSL7.7%Median -47.5%

Net Margin

Higher is better
CRNX-2,747.2%TLX-0.9%MSB-115.3%CSL9.2%Median -125.7%

Revenue Growth

Higher is better
CRNX2,277.5%TLX56.3%MSB410.4%CSL4.8%Median 5.1%

P/E

Lower is better
CRNX—VKTX—ACAD11.85EWTX—TNGX—DNLI—Median 17.81

ROE

Higher is better
CRNX-39.2%VKTX-70.0%ACAD37.3%EWTX-38.1%TNGX-38.4%DNLI-49.6%Median -47.5%

Net Margin

Higher is better
CRNX-2,747.2%VKTX—ACAD34.3%EWTX—TNGX-188.2%DNLI—Median -125.7%

Revenue Growth

Higher is better
CRNX2,277.5%VKTX—ACAD9.9%EWTX-100.0%TNGX39.0%DNLI—Median 5.1%

All Metrics

Valuation
MetricCRNXTLXMSBCSLInd. Median
P/E———30.0217.81
P/B3.426.56—2.24●3.49
EV/EBITDA—123.31—10.37●14.92
P/S242.143.3431.912.67●10.89
Financial Health
MetricCRNXTLXMSBCSLInd. Median
Current Ratio18.60●1.43—2.575.90
Debt/Equity3.7%●112.3%—67.4%10.9%
NetDebt/EBITDA2.5313.13—2.22●1.15
Profitability
MetricCRNXTLXMSBCSLInd. Median
Net Margin-2,747.2%-0.9%-115.3%9.2%●-125.7%
ROE-39.2%-1.8%-11.3%7.7%●-47.5%
ROA-35.9%-0.7%-8.6%3.8%●-35.8%
EBITDA Margin-2,723.4%3.0%-76.6%32.8%●-105.8%
Growth + Dividend
MetricCRNXTLXMSBCSLInd. Median
Rev. Growth2,277.5%●56.3%410.4%4.8%5.1%
NI Growth———-39.4%12.1%
Div. Yield——0.0%2.5%●0.2%
Payout——0.0%103.1%0.0%
Valuation
MetricCRNXVKTXACADEWTXTNGXDNLIInd. Median
P/E——11.85———17.81
P/B3.42●8.913.578.7110.985.193.49
EV/EBITDA——28.76———14.92
P/S242.14—4.06●—75.43—10.89
Financial Health
MetricCRNXVKTXACADEWTXTNGXDNLIInd. Median
Current Ratio18.605.723.5922.6127.38●9.285.90
Debt/Equity3.7%—4.1%0.8%●8.4%4.3%10.9%
NetDebt/EBITDA2.53—-6.31●2.823.301.921.15
Profitability
MetricCRNXVKTXACADEWTXTNGXDNLIInd. Median
Net Margin-2,747.2%—34.3%●—-188.2%—-125.7%
ROE-39.2%-70.0%37.3%●-38.1%-38.4%-49.6%-47.5%
ROA-35.9%-64.0%27.4%●-36.2%-30.2%-40.0%-35.8%
EBITDA Margin-2,723.4%—11.6%●—-184.5%—-105.8%
Growth + Dividend
MetricCRNXVKTXACADEWTXTNGXDNLIInd. Median
Rev. Growth2,277.5%●—9.9%-100.0%39.0%—5.1%
NI Growth——64.1%———12.1%
Div. Yield——————0.2%
Payout——————0.0%

The green dot marks the best value in the group given the metric direction (higher/lower is better). All metrics use trailing-twelve-month (TTM) data.

Go deeper on CRNX

Run a DCF valuation

Full DCF model with editable assumptions

Start a head-to-head duel

Compare two stocks metric by metric

Filter in the stock screener

Build your own universe with 400+ metrics

Data on this page refreshes once per day. Price data as of Jul 6, 26. This content is for informational purposes only and is not investment advice.